CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
Irondietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02233322
NCT02233322N/ACompleted
CompareCT.gov

Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot

Indiana University·interventional·Posted Sep 8, 2014·Updated Nov 14, 2019

In Brief

A clinical study evaluating Iron for Autosomal Dominant Hypophosphatemic Rickets. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (ADHR). ADHR is an inherited disorder in which the body makes too much FGF 23 and causes low blood phosphorus levels and bone problems such as rickets (bowed legs in children) or bone pain and weakness in adults. This study is to test whether or not giving iron helps correct the high FGF23 and there by correcting the phosphate problem.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutosomal Dominant Hypophosphatemic Rickets
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 8, 2014
Enrollment StartAug 1, 2014
Primary CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.8 years ago

Interventions

Irondietary

All subjects will receive iron supplementation based on iron levels in the blood